Merger of equals to create new global critical minerals champion and unlock substantial valueVANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. "The merger of equals between Teck and Anglo American announced this quarter is a unique opportunity to create a global leader in critical minerals and a top five copper producer," said Jonathan Price, President and CEO. "The c ...

Core Insights - Borregaard's operating revenues for Q3 2025 were NOK 1,799 million, a decrease from NOK 1,949 million in Q3 2024 [1] - EBITDA fell to NOK 440 million from NOK 524 million year-over-year [1] - Profit before tax decreased to NOK 247 million from NOK 326 million, and earnings per share dropped to NOK 1.96 from NOK 2.51 [3] Revenue and Performance Analysis - The decline in EBITDA was attributed to lower bioethanol prices and a temporary disruption in cellulose production at the Sarpsborg site, which had an estimated negative impact of NOK 40 million [2] - BioSolutions experienced growth in sales to agriculture, contributing positively to the overall results [2] - In BioMaterials, higher sales prices were offset by lower sales volume, while Fine Chemicals showed strong performance [2] Management Commentary - The CEO, Tom Erik Foss-Jacobsen, expressed satisfaction with the strong agricultural sales and the company's ability to deliver solid results amid uncertain global conditions, highlighting the strength and flexibility of Borregaard's business model [3]

By the end of the Q3 2025, Coop Pank had 222,000 customers, increased by 4,000 customers in the quarter (+2%) and by 20,000 in the year (+10%). The bank had 105,400 active customers, increased by 1,800 (+2%) in the quarter and by 10,000 (+10%) in the year. In Q3 2025, volume of deposits in Coop Pank increased by 105 million euros (+6%), reaching total of 1.91 billion euros. Deposits from private customers increased by 9 million euros: demand deposits remained at the same level compared to the previous quar ...

Core Insights - BAWAG Group reported a strong operating performance for Q3 2025, with a net profit of €219 million, earnings per share of €2.77, and a return on tangible common equity (RoTCE) of 27.8% [1][3] - The company achieved a net profit of €630 million and earnings per share of €7.98 for the first nine months of 2025, reflecting a solid financial position [1][3] - The CET1 ratio stood at 14.1% after accounting for a dividend accrual of €346 million, indicating a robust capital position [2] Financial Performance - Core revenues for Q3 2025 reached €554 million, a 43% increase year-over-year, while year-to-date core revenues totaled €1,636.7 million, up 40% [5] - Net interest income for Q3 was €460 million, up 48% year-over-year, and year-to-date net interest income was €1,363.4 million, an increase of 45% [5] - Operating expenses increased by 58% in Q3 to €200.3 million, with year-to-date operating expenses at €604.6 million, up 59% [5] - The net profit for Q3 was €218.5 million, a 23% increase compared to the previous year, and the profit before tax was €293.5 million, up 23% [5] Shareholder Returns - The company executed a €175 million share buyback in Q3 2025, canceling 1.6 million shares, resulting in 77 million shares outstanding, a reduction of 23% since the IPO in 2017 [2][4] - The liquidity coverage ratio (LCR) was reported at 201%, reflecting a strong liquidity position despite a decrease of 59 basis points [5] Strategic Outlook - BAWAG Group expects to outperform its full-year targets for 2025 and reconfirms its mid-term targets as presented during the Investor Day on March 4, 2025 [3] - The integration of recent acquisitions is progressing well, serving as a catalyst for organizational redesign towards a digital-first banking approach [5]

Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics’ shareholders will be eligible to receive a closing purchase price of 350 ...

Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding. Th ...

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels Phase 2 data support both three-week and four-week dosing regimens for efdoralprin alfa - a potentially significant i ...

Core Insights - Adlai Nortye Ltd. is set to present its novel CEACAM5-targeting antibody-drug conjugate (ADC), AN4035, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025 [1][4]. Group 1: AN4035 Development - AN4035 is designed to address the limitations of current pan-RAS(ON) inhibitors by targeting tumors directly, thereby reducing systemic toxicities and widening the therapeutic window [2][3]. - The ADC approach of AN4035 aims to improve efficacy while minimizing on-target, off-tumor toxicities, particularly for RAS-addicted tumors such as colorectal cancer [3][6]. Group 2: Presentation Details - The oral presentation will take place on October 25, 2025, from 11:45 AM to 12:15 PM ET, focusing on novel therapeutic agents [4]. - A poster presentation will also be held on the same day, showcasing the discovery of AN4035 [4]. Group 3: Efficacy and Safety - AN4035 has shown strong intracellular payload retention and significant cytotoxicity in CEACAM5-positive/RAS-addicted cancer cell lines, achieving a 73% objective response rate in a patient-derived xenograft trial with 26 participants [5]. - Preliminary toxicology results in cynomolgus monkeys indicate a favorable safety profile for AN4035 [5]. Group 4: Company Overview - Adlai Nortye is a clinical-stage biotechnology company focused on innovative cancer therapies, with R&D centers in the U.S. and China [7]. - The company is advancing a portfolio that includes next-generation PD-1/L1 modulation and RAS-targeted therapies, highlighting its commitment to developing transformative oncology treatments [7].

Core Insights - iCAUR is evolving from a mobility brand to a lifestyle brand, aiming to redefine how people move in the next decade [2][4] - The brand emphasizes the creation of classic cars for the new energy era, focusing on personality and style [5][11] - iCAUR plans to expand its global presence, targeting over 100 countries in the next five years [12][15] Brand Vision and Strategy - iCAUR has established a market network covering 28 countries and regions, with plans to develop over 200 new ecosystem products annually [4] - The brand's globalization strategy includes deep integration of brand concepts, service systems, and user value [4] - iCAUR aims to become a world-leading new energy vehicle (NEV) brand, with its first model, the V23, exceeding market expectations [12] Product Development and Design - iCAUR follows the 5R principles—Respect, Responsibility, Rigor, Reliability, and Relationship—in product development [8] - The V27 model features a 1.5T engine with a thermal efficiency of 44.5%, showcasing high-quality technology and versatility [8] - The design philosophy of "Less is truer" focuses on minimalist aesthetics that connect with users, aiming for timeless beauty [9] Market Engagement and Expansion - The V27 received significant attention, with over 20 billion views and coverage in more than 100 countries [12] - Distribution agreements were signed with partners from the UAE, South Africa, and Paraguay, marking a new chapter in global expansion [17] - iCAUR's vision of "Classic Never Fades" drives its innovation and co-creation efforts in the new energy sector [20]

Core Insights - Nokia has partnered with ST Engineering and First One Systems to deploy an IP/MPLS-based mission-critical Backbone Transmission Network (BTN) for Bangkok's new MRT Orange Line, expected to be completed by 2030 [1][2][9] - The project aims to enhance safety and services for the Mass Rapid Transit system, supporting various applications such as CCTV surveillance, public announcements, and passenger information displays [2][9] Group 1: Project Overview - The Orange Line will span 35.9 km, connecting the east and west sides of Bangkok with both underground and elevated transit systems [3] - The deployment of Nokia's solution will provide a high-capacity, low-latency, reliable, and secure transmission backbone for the railway [2][9] Group 2: Technical Specifications - Nokia will develop two BTNs with network speeds of 10G and 40G to facilitate voice, data, and video transmission between stations and the Operations Control Center (OCC) [6] - The solution includes the Nokia 7250 Interconnect Router, Nokia 7210 Service Access System, and a service management platform, aimed at simplifying operations and maintenance while enhancing network performance visibility [6][9] Group 3: Collaboration and Expertise - The collaboration involves deep technical expertise and seamless integration capabilities from all partners, ensuring the communication system meets international standards [4][5] - Nokia's experience in delivering similar railway projects globally provides confidence in overcoming potential challenges [5]